MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...

George Evans had the opportunity of a lifetime as he stepped up to the mound to throw the first pitch at the Athletics game against the Houston Astros ...

A program where interested staff members receive additional training on cancer treatment effects and pet care, becoming ...

New research from Indiana University shows that Black Americans have higher incidence of pancreatic cancer but aren't ...

Seven-year follow-up data on over 1400 patients show radium-223's long-term safety, with a low 2% secondary malignancy rate, reflecting real-world use.

Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.

Adding niraparib to AAP and ADT improved rPFS in mCSPC patients with HRR mutations in the phase 3 AMPLITUDE trial.

BMS entered the radiopharma space via its $4.1 billion buyout of RayzeBio at the end of 2023. Unlike Novartis’ approved ...

A recent study from the Institute of Biomedicine at the University of Eastern Finland shows that the glucocorticoid receptor can both promote and ...

Acupuncture produced significantly greater reductions in nocturia episodes and IPSS scores in survivors of prostate cancer ...

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.